Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Geron Corp GERN

Alternate Symbol(s):  GERNW

Healthcare Biotechnology
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the... see more

Recent & Breaking News (NDAQ:GERN)

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 3 days ago

Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

Business Wire 13 days ago

Geron to Participate in the Stifel 2024 Healthcare Conference

Business Wire 13 days ago

Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million

GlobeNewswire November 7, 2024

Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors

Business Wire November 7, 2024

Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Business Wire November 7, 2024

Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO(TM) (imetelstat) in Myeloid Hematologic Malignancies

Business Wire November 5, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 17, 2024

Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024

Business Wire October 15, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 19, 2024

Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

Business Wire September 9, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 22, 2024

Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights

Business Wire August 8, 2024

Geron Announces Updated NCCN Guidelines® Recommending RYTELO(TM) (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

Business Wire July 26, 2024

Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024

Business Wire July 23, 2024

Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

Business Wire July 18, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 20, 2024

Geron Announces FDA Approval of RYTELO(TM) (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Business Wire June 6, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 16, 2024

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

Business Wire May 2, 2024